No Matter What The FDA Decides, New Diabetes Drugs Will Still Require CV Outcomes Trials

No Matter What The FDA Decides, New Diabetes Drugs Will Still Require CV Outcomes Trials

Source: 
Forbes
snippet: 

At one time, Avandia (generic name: rosiglitazone) was a major diabetes drug for GSK with sales exceeding $3 billion annually. Like all drugs to treat diabetes, Avandia had received regulatory approval based on its ability to lower blood sugar which, if left untreated, can result in diabetic complication such as kidney disease, blindness, amputations and heart attacks. However, after being on the market for a number of years, a retrospective analysis conducted by Dr. Steven Nissen and Ms. Kathy Wolski at the Cleveland Clinic found that, rather than reduce heart attacks and strokes, Avandia use in diabetics resulted in an INCREASE in heart attacks and deaths in patients.